Stomach/IntestinePostoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis
Section snippets
Criteria for patient selection and propensity score matching
We reviewed the medical records of our prospectively collected database of 1,078 patients who underwent gastrectomy for GC at the Department of Gastroenterological Surgery, Nagoya University between January 1999 and July 2014. Patients were selected if they met the eligibility criteria as follows: pathologically confirmed adenocarcinoma of the stomach, histologically confirmed R0 gastric resection (D2) with negative resection margins, pathologic evaluation of the number of resected lymph nodes
Patient characteristics of patients before and after propensity score matching
Patients categorized either as surgery alone or S-1 adjuvant were matched one-to-one by the use of propensity score matching and 70 pairs of patients were generated, and the resulting score-matched pairs were used in subsequent analyses. Fifteen patients were categorized in the surgery alone group after standardization of S-1 adjuvant in Japan (2007) because of patient refusal including an economic reason. Demographics and preoperative clinical characteristics of unmatched and matched
Discussion
The prognosis of patients with GC depends primarily on their stage. The prognosis of patients with Stage I GC, in which the tumor is limited to pT1 or pT2N0, is excellent with low risk for recurrences,16 and adjuvant therapy is not indicated for this population. In contrast, patients with Stage IV GC almost invariably suffer from dismal prognosis and should undergo systemic chemo- or chemoradiation therapy, palliative surgery, or best supportive care with curative resection reserved for
References (34)
- et al.
Management of gastric cancer in Asia: resource-stratified guidelines
Lancet Oncol
(2013) - et al.
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
Lancet Oncol
(2010) - et al.
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Lancet
(2010) - et al.
Estimated pancreatic parenchymal remnant volume accurately predicts clinically relevant pancreatic fistula after pancreatoduodenectomy
Surgery
(2014) - et al.
Gastric cancer
Lancet
(2009) - et al.
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol
(2010) - et al.
A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study)
Eur J Surg Oncol
(2009) - et al.
Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle–a new strategy against peritoneal dissemination of gastric cancer
Cancer Lett
(2008) - et al.
Global cancer statistics
CA Cancer J Clin
(2011) - et al.
Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer
J Exp Clin Cancer Res
(2014)
Prognostic value of early postoperative tumor marker response in gastric cancer
Ann Surg Oncol
D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer
N Engl J Med
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis
J Am Med Assoc
Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer
J Clin Oncol
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
N Engl J Med
Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer
Gastric Cancer
Cited by (52)
Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial
2021, Contemporary Clinical Trials CommunicationsCitation Excerpt :Nevertheless, the DCF regimen may be toxic, requiring development of a regimen that is equally effective and less toxic in the setting of preoperative chemotherapy. For example, the oral fluoropyrimidine S-1 achieves efficacious concentrations of plasma 5-fluorouracil while reducing adverse gastrointestinal effects [14]. To test the safety and efficacy of S-1-based neoadjuvant treatment for clinical stage III ESCC, we previously performed a phase II clinical trial of two courses of neoadjuvant S-1 plus cisplatin [15].
Expression of cellular retinoic acid binding protein 1 predicts peritoneal recurrence of gastric cancer
2022, International Journal of Oncology